{"id":382074,"date":"2020-11-16T12:50:53","date_gmt":"2020-11-16T17:50:53","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=382074"},"modified":"2020-11-16T12:50:53","modified_gmt":"2020-11-16T17:50:53","slug":"processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/","title":{"rendered":"Processa Pharmaceuticals to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<h2>\nProcessa\u2019s pipeline includes several clinical-stage drug candidates<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>HANOVER, MD., Nov.  16, 2020  (GLOBE NEWSWIRE) &#8212; via InvestorWire \u2013 Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (\u201cProcessa\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing products to improve the survival and\/or quality of life for patients who have unmet medical needs, announced today that management will participate in two upcoming investor conferences:<\/p>\n<p>\n        <u>Craig-Hallum Alpha Select Virtual Conference<\/u>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:0in;margin-bottom:0in\">Tuesday, Nov. 17, 2020 (one-on-one meetings only)<\/li>\n<\/ul>\n<p>\n        <u>Benchmark Annual Discovery 1&#215;1 Investor Virtual Conference<\/u><br \/>\n        \n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:0in;margin-bottom:0in\">Wednesday, Nov. 18, 2020 (one-on-one meetings only)<\/li>\n<\/ul>\n<p>\n        <strong>To schedule a one-on-one meeting with management<\/strong>, please contact your conference representative or <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mAG8CWgG0xq8wmuKKd-mhFYlfTxnljctqNP58p4a00kd28j6vwJn84iMuRsiaFh6n-b_6zVOzj4-SobFupRyBOQiz6qXWjmcQA9_5A0mhxM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>James@HaydenIR.com<\/u><\/a>. <\/p>\n<p>\n        <strong>About Processa Pharmaceuticals, Inc.<\/strong>\n      <\/p>\n<p>The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and\/or quality of life. The Company used these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility\/gastroparesis). The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OCVxLuVFmWz3jpu7S4LlPKDPruIBgu3zQZFNUyG1x2nrm0-DqcITNXL7jCRpbLd_MyDg8qP5WhDakjPy5guN3Y_dSnW6PvlKzHhK2RvwRGo=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.ProcessaPharma.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This release contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Please refer to the registration statement relating to the securities being sold in this offering, which identifies important risk factors which could cause actual results to differ from those contained in the forward-looking statements.<\/p>\n<p>For More Information:\u00a0<br \/> Michael Floyd\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=i6fiEEOJWxiEJ-H8QrcAfQeu3jTbdEHb7_xnezo_dHFF9TdCKYfRo_204hx9-iMbyL9oQvTGj5JSHY2HsTlbrB7Lo-Gk1muQp9s9mQ3VjEwWQZybapgnBGMGIilWQ9aqAeDJvp0GigYywLkCrI9U4yEHOA2VYNW3FaNzDKw5KgyQXyaYyQ6WEkCiiu46NbF7K2nDYKp5k6QnR8RoUrzrs6Fp-QabDRBlnRqHPtt0KYGG2Lvk0KNWqXbglzZiR0YytyeofqGcKy39LX1B7omjX-N_p7EeSuNvhdrAj8o-1UBzx5Z2SxaiEhroNN5-Vk8fs7muZigj3UnLICFDJy7IlA1UvjCyhl1ZNOv_hseQGvVKZ23z8-GMDn2NwYxFQHvFaOOmWDQAjGy9NYWBGTa8-_P2GAWOubHKTVD7MgUmvZBRQ-WdgHrgZFyp2SgRzrgm7eV9BaTMXm5qnSKJ9onlACSsJW5krWXn0pq2W1eH31MFe6qBOEouhRT2hBfr1uqf\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong><u>mfloyd@processapharma.com\u00a0<\/u><\/strong><\/a><br \/> 301-651-4256<\/p>\n<p>James Carbonara\u00a0<br \/> Hayden IR\u00a0<br \/> (646) 755-7412\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rFFAB48RrwzCbL5RHomvL5sZ2QbB2O9-OddnZYq4-vADE58dslCP-vKT3Ersxk9C-Oo6tIKdNLRpZCxxTRvYJXRrYpkJRG33P_96VkRyW-ipZJF6DXM-ygMcCdMJHpAFjjmbclrD5XJ-6abo76G5aWxcg1oFNhRSBRfQJByVAAToBVoBaCv8N3qQqb303u5iHz5dS2wCyCd4CXb4YN9RUZveSVtZC_9dZxtVujt1tROlkDC5O-z103jjgP0vUTlq\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong><u>james@haydenir.com<\/u><\/strong><\/a><\/p>\n<p>\n        <strong>Corporate Communications:\u00a0<\/strong><br \/>\n        <br \/> InvestorBrandNetwork (IBN)\u00a0<br \/> Los Angeles, California\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=r9_yvbYIPEotTihk9gka4WJ9knE8ek7wWcaKD3ExjhWwXlzrPpjms-XIBxpjbe6iwar0pm5vqx5znK_T2uC9j-TEG2jPcNhAXpocovtJzD-VBAxvLk5Ms6ONG5dxULUJEgh5kBm29w36xE5H6xfKzDUCUJs95dcGzMmtctf-MGTwp9rzVlwwQdCpyj8rZhYlEvt5_OHQf2AOSdwPlxo5l7u1bhVLGGE1SnINZfjn8KOllq59DtbSSKIz1ruihe_ym4CqXHd9JwnCNZ84O_KZQlK3iDN8_hKV15l6FcSXdaw=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong><u>www.InvestorBrandNetwork.com<\/u><\/strong><strong>\u00a0<\/strong><\/a><br \/> 310.299.1717 Office\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NEkG47HImqAmKdcTTAedGyPaCqUFCPiSrXbMbWwq4d0vkP5HyQhxdaz74n3IgghKghVztX6HgbJj0VDOEPxTuaT5i8kjl_-iPq5e1xizzqnwBoGng2sczAe8ubjKtIReUjVCK-1Nb5raTLPN6hOdJ2l_m8qB8wwz4vAx-5R82WpP-sT024JcLzo129-ZmUNwbyPsKai08BgfnYKNymBPqtsTwJGQGXWp3toMallL-OwY5eGQ8KJKdqZyy9-IQRUCC6wqxX0ZS20zQh1abyTmXp0BbI8RrPS0--Kx3Gdi9nkD8Hz5Tao20pV9tVIP3pUDj8DI3lRZvcQo7dqKPjGXBvqO4BbrejJltRUxgqGYKLbR0fk3Ve3DlyXTpGHS3o_PKDu65fZNUXMnE3UO_klvun58SdO0Yy9TFKJl0ulCjuBaF25tfzgUeg46nDGkvDL0bV0d9kw5bAs5y8ZevU9esgoCBsYMX8tkmwONpUISTDbUiJEHHgj8BY8o9TuiS0enophJst7CaNh_mzF4HGhmT7vbVZJ2iAwdaAlJqFOjeo9NpuF39I4Tr9ieBtuGw6b3\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong><u>Editor@InvestorBrandNetwork.com<\/u><\/strong><\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjkxOCMzODI5NTk0IzUwMDA3NTM5Mg==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/53173c7e-7ceb-467b-b65d-6a12f1fcddb4\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Processa\u2019s pipeline includes several clinical-stage drug candidates HANOVER, MD., Nov. 16, 2020 (GLOBE NEWSWIRE) &#8212; via InvestorWire \u2013 Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (\u201cProcessa\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing products to improve the survival and\/or quality of life for patients who have unmet medical needs, announced today that management will participate in two upcoming investor conferences: Craig-Hallum Alpha Select Virtual Conference Tuesday, Nov. 17, 2020 (one-on-one meetings only) Benchmark Annual Discovery 1&#215;1 Investor Virtual Conference Wednesday, Nov. 18, 2020 (one-on-one meetings only) To schedule a one-on-one meeting with management, please contact your conference representative or James@HaydenIR.com. About Processa Pharmaceuticals, Inc. The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Processa Pharmaceuticals to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-382074","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Processa\u2019s pipeline includes several clinical-stage drug candidates HANOVER, MD., Nov. 16, 2020 (GLOBE NEWSWIRE) &#8212; via InvestorWire \u2013 Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (\u201cProcessa\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing products to improve the survival and\/or quality of life for patients who have unmet medical needs, announced today that management will participate in two upcoming investor conferences: Craig-Hallum Alpha Select Virtual Conference Tuesday, Nov. 17, 2020 (one-on-one meetings only) Benchmark Annual Discovery 1&#215;1 Investor Virtual Conference Wednesday, Nov. 18, 2020 (one-on-one meetings only) To schedule a one-on-one meeting with management, please contact your conference representative or James@HaydenIR.com. About Processa Pharmaceuticals, Inc. The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with &hellip; Continue reading &quot;Processa Pharmaceuticals to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-16T17:50:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjkxOCMzODI5NTk0IzUwMDA3NTM5Mg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Processa Pharmaceuticals to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2020-11-16T17:50:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/\"},\"wordCount\":335,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NjkxOCMzODI5NTk0IzUwMDA3NTM5Mg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/\",\"name\":\"Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NjkxOCMzODI5NTk0IzUwMDA3NTM5Mg==\",\"datePublished\":\"2020-11-16T17:50:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NjkxOCMzODI5NTk0IzUwMDA3NTM5Mg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NjkxOCMzODI5NTk0IzUwMDA3NTM5Mg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Processa Pharmaceuticals to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"Processa\u2019s pipeline includes several clinical-stage drug candidates HANOVER, MD., Nov. 16, 2020 (GLOBE NEWSWIRE) &#8212; via InvestorWire \u2013 Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (\u201cProcessa\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing products to improve the survival and\/or quality of life for patients who have unmet medical needs, announced today that management will participate in two upcoming investor conferences: Craig-Hallum Alpha Select Virtual Conference Tuesday, Nov. 17, 2020 (one-on-one meetings only) Benchmark Annual Discovery 1&#215;1 Investor Virtual Conference Wednesday, Nov. 18, 2020 (one-on-one meetings only) To schedule a one-on-one meeting with management, please contact your conference representative or James@HaydenIR.com. About Processa Pharmaceuticals, Inc. The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with &hellip; Continue reading \"Processa Pharmaceuticals to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-16T17:50:53+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjkxOCMzODI5NTk0IzUwMDA3NTM5Mg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Processa Pharmaceuticals to Participate in Upcoming Investor Conferences","datePublished":"2020-11-16T17:50:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/"},"wordCount":335,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjkxOCMzODI5NTk0IzUwMDA3NTM5Mg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/","name":"Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjkxOCMzODI5NTk0IzUwMDA3NTM5Mg==","datePublished":"2020-11-16T17:50:53+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjkxOCMzODI5NTk0IzUwMDA3NTM5Mg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NjkxOCMzODI5NTk0IzUwMDA3NTM5Mg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/processa-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Processa Pharmaceuticals to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/382074","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=382074"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/382074\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=382074"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=382074"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=382074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}